Cormorant Asset Management as of March 31, 2024
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 57 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 18.7 | $427M | 8.5M | 50.23 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 6.3 | $143M | 6.9M | 20.67 | |
| Arcellx Common Stock (ACLX) | 5.4 | $124M | 1.8M | 69.55 | |
| Alpine Immune Sciences | 4.7 | $107M | 2.7M | 39.64 | |
| Bridgebio Pharma (BBIO) | 4.3 | $99M | 3.2M | 30.92 | |
| Praxis Precision Medicines I Com New (PRAX) | 3.5 | $80M | 1.3M | 61.02 | |
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 3.5 | $80M | 2.0M | 39.24 | |
| Tarsus Pharmaceuticals (TARS) | 3.4 | $78M | 2.1M | 36.35 | |
| Longboard Pharmaceuticals In | 3.2 | $72M | 3.4M | 21.60 | |
| Edgewise Therapeutics (EWTX) | 2.4 | $55M | 3.0M | 18.24 | |
| Crinetics Pharmaceuticals In (CRNX) | 2.4 | $54M | 1.2M | 46.81 | |
| Biomea Fusion (BMEA) | 2.3 | $53M | 3.6M | 14.95 | |
| Korro Bio (KRRO) | 2.1 | $48M | 529k | 90.00 | |
| Vaxcyte (PCVX) | 2.1 | $47M | 685k | 68.31 | |
| Autolus Therapeutics Spon Ads (AUTL) | 1.9 | $42M | 6.6M | 6.38 | |
| Pharvaris N V (PHVS) | 1.7 | $40M | 1.7M | 23.11 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.6 | $36M | 1.5M | 23.65 | |
| Cg Oncology (CGON) | 1.5 | $35M | 800k | 43.90 | |
| Alx Oncology Hldgs (ALXO) | 1.5 | $35M | 3.1M | 11.15 | |
| Biohaven (BHVN) | 1.5 | $34M | 617k | 54.69 | |
| Merus N V (MRUS) | 1.4 | $32M | 715k | 45.03 | |
| Aerovate Therapeutics (AVTE) | 1.4 | $32M | 1.1M | 29.57 | |
| Abivax Sa Sponsored Ads (ABVX) | 1.3 | $31M | 2.1M | 14.30 | |
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 1.3 | $30M | 2.9M | 10.40 | |
| Marinus Pharmaceuticals Com New | 1.3 | $29M | 3.3M | 9.04 | |
| Tourmaline Bio (TRML) | 1.3 | $29M | 1.3M | 22.90 | |
| Janux Therapeutics (JANX) | 1.2 | $28M | 750k | 37.65 | |
| Neurogene (NGNE) | 1.2 | $27M | 539k | 50.90 | |
| Cargo Therapeutics (CRGX) | 1.2 | $26M | 1.2M | 22.32 | |
| Rhythm Pharmaceuticals (RYTM) | 1.0 | $24M | 550k | 43.33 | |
| Apellis Pharmaceuticals (APLS) | 1.0 | $24M | 400k | 58.78 | |
| Arcutis Biotherapeutics (ARQT) | 0.9 | $21M | 2.1M | 9.91 | |
| Ideaya Biosciences (IDYA) | 0.9 | $20M | 450k | 43.88 | |
| Cabaletta Bio (CABA) | 0.8 | $19M | 1.1M | 17.06 | |
| Astria Therapeutics (ATXS) | 0.8 | $18M | 1.3M | 14.07 | |
| Engene Holdings (ENGN) | 0.7 | $17M | 1.0M | 16.95 | |
| Insmed Com Par $.01 (INSM) | 0.7 | $16M | 575k | 27.13 | |
| Ventyx Biosciences (VTYX) | 0.7 | $15M | 2.7M | 5.50 | |
| Nkarta (NKTX) | 0.6 | $15M | 1.4M | 10.81 | |
| Silence Therapeutics Ads (SLN) | 0.6 | $14M | 625k | 21.60 | |
| Mersana Therapeutics | 0.5 | $12M | 2.6M | 4.48 | |
| Compass Therapeutics (CMPX) | 0.5 | $11M | 5.6M | 1.98 | |
| Kyverna Therapeutics (KYTX) | 0.5 | $11M | 440k | 24.84 | |
| Beam Therapeutics Put Option (BEAM) | 0.4 | $9.9M | 300k | 33.04 | |
| Immuneering Corp Class A Com (IMRX) | 0.4 | $9.5M | 3.3M | 2.89 | |
| Spyre Therapeutics Com New (SYRE) | 0.4 | $9.5M | 250k | 37.93 | |
| Arrivent Biopharma (AVBP) | 0.4 | $9.2M | 515k | 17.86 | |
| Rocket Pharmaceuticals (RCKT) | 0.4 | $8.1M | 300k | 26.94 | |
| Disc Medicine (IRON) | 0.3 | $7.8M | 125k | 62.26 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.3 | $6.3M | 562k | 11.30 | |
| Gh Research Ordinary Shares (GHRS) | 0.3 | $6.3M | 593k | 10.66 | |
| Stoke Therapeutics (STOK) | 0.3 | $5.8M | 427k | 13.50 | |
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 0.2 | $4.7M | 75k | 62.24 | |
| Verve Therapeutics (VERV) | 0.2 | $4.6M | 350k | 13.28 | |
| Rapt Therapeutics | 0.2 | $4.5M | 497k | 8.98 | |
| Vyne Therapeutics (VYNE) | 0.2 | $4.3M | 1.4M | 3.07 | |
| Bioatla (BCAB) | 0.2 | $4.0M | 1.2M | 3.44 |
